Payment overview · 2025
General Payments
$1,108.61
40 reported records · 12 companies
Healthcare provider profile · identity verified
Michael C Tushla, MD
Allopathic & Osteopathic Physicians|Family Medicine · SANTA PAULA, CA · NPI 1811076961
Verified facts
What the public records show
CMS Open Payments records show Michael C Tushla, MD received $1,108.61 in general payments during 2025 across 40 reported records.
Amgen Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $264.34 | 23.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $221.04 | 19.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.72 | 15.3% | 7 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $139.00 | 12.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $89.41 | 8.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $57.79 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.08 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.05 | 4.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.31 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.61 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.49 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.77 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $933.61 | 39 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $199.27 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $139.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.61 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.27 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $89.41 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.43 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.47 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $57.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.87 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
158 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
46 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 977 | 282 |
| Losartan Potassium | Losartan Potassium | 667 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 533 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 461 | 125 |
| Omeprazole | Omeprazole | 445 | 139 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 376 | 68 |
| Metformin Hcl | Metformin Hcl | 374 | 115 |
| Lisinopril | Lisinopril | 317 | 92 |
| Gabapentin | Gabapentin | 269 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 72 |
| Alprazolam | Alprazolam | 225 | 54 |
| Alendronate Sodium | Alendronate Sodium | 213 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 204 | 49 |
| Jardiance | Empagliflozin | 196 | 48 |
| Furosemide | Furosemide | 187 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 30 |
| Trazodone Hcl | Trazodone Hcl | 167 | 44 |
| Sertraline Hcl | Sertraline Hcl | 166 | 52 |
| Eliquis | Apixaban | 158 | 34 |
| Azithromycin | Azithromycin | 155 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 45 |
| Simvastatin | Simvastatin | 148 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 46 |
| Cefuroxime | Cefuroxime Axetil | 141 | 115 |
| Meloxicam | Meloxicam | 136 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 135 | 69 |
| Baclofen | Baclofen | 131 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 46 |
| Tramadol Hcl | Tramadol Hcl | 130 | 68 |
| Famotidine | Famotidine | 127 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 35 |
| Azelastine Hcl | Azelastine Hcl | 119 | 49 |
| Potassium Chloride | Potassium Chloride | 118 | 35 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 108 | 70 |
| Lorazepam | Lorazepam | 102 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 80 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 31 |
| Carvedilol | Carvedilol | 87 | 27 |
| Xarelto | Rivaroxaban | 86 | 18 |
| Doxepin Hcl | Doxepin Hcl | 79 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 24 |
| Ketoconazole | Ketoconazole | 78 | 41 |
| Allopurinol | Allopurinol | 77 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 24 |
| Prednisone | Prednisone | 77 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Benazepril Hcl | Benazepril Hcl | 74 | 20 |
| Valsartan | Valsartan | 73 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 24 |
| Finasteride | Finasteride | 71 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 21 |
| Trulicity | Dulaglutide | 68 | 13 |
| Naproxen | Naproxen | 65 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 21 |
| Estradiol | Estradiol | 63 | 18 |
| Glipizide | Glipizide | 62 | 20 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Mupirocin | Mupirocin | 62 | 39 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | 18 |
| Januvia | Sitagliptin Phosphate | 61 | 18 |
| Ezetimibe | Ezetimibe | 60 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 15 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 16 |
| Ibuprofen | Ibuprofen | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 52 | 22 |
| Methylprednisolone | Methylprednisolone | 52 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 29 |
| Ozempic | Semaglutide | 46 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 46 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 40 | 31 |
| Spironolactone | Spironolactone | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Pregabalin | Pregabalin | 34 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 24 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | 12 |
| Diazepam | Diazepam | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 28 | 23 |
| Atenolol | Atenolol | 26 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | 11 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 14 |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 14 |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,108.61 · 40 records | Amgen Inc. | AIRSUPRA, AMVUTTRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, JARDIANCE, Leqembi, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Tymlos, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error